• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine >Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor
【24h】

Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor

机译：VEGFR 1-3中的不同表达模式在胃肠内科神经内分泌肿瘤中：支持临床相关性，但不是预后因素

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are an increasing tumor entity. Since many patients are diagnosed at an advanced stage, treatment is still challenging and dependent on many tumor and patient specific factors. Therefore, the aim of the present study was to elucidate the expression rates and the prognostic value of vascular endothelial growth factor receptor (VEGFR) 1-3 in GEP-NENs. A potential association to immune checkpoint markers was further investigated. Material and Methods: The expression levels of VEGFR 1-3 were analyzed by immunohistochemistry and correlated with the expression of the checkpoint markers PD-1 and PD-L1. Furthermore, the tumor samples of 249 GEP-NEN patients were studied and correlated with overall survival rates and clinicopathological features. Kaplan–Meier analyses and the log rank test were used for survival analyses. Categorical variables were compared by the χ2 test. Results: The most common primary tumor site was the small intestine (50.6%), followed by the pancreas (25.7%). VEGFR 1 was highly expressed in 59%, VEGFR 2 in 6.4%, and VEGFR 3 in 61.8% of the analyzed samples. The expression of VEGFR 1-3 was not significantly associated with survival rates. Pancreatic NENs had the highest expression of VEGFR 1 and 3 in 80% of the cases. VEGFR 1-3 positivity correlated with the expression levels of immune checkpoint markers. Discussion: VEGFR 1-3 show a distinct expression pattern in different subgroups of neuroendocrine neoplasias indicating a conceivable target. Moreover, there was a substantial association between VEGFRs and immune checkpoint markers. Taken together, anti-VEGFR therapy represents a promising therapeutic approach in GEP-NEN patients and should be addressed in future studies.
机译：介绍：胃肠内科神经内分泌肿瘤（GEP- NENS）是一种增加的肿瘤实体。由于许多患者被诊断为晚期阶段，因此治疗仍然挑战，依赖于许多肿瘤和患者的特定因素。因此，本研究的目的是阐明血管内皮生长因子受体（VEGFR）1-3的表达率和预后值在GEP- NENS中。进一步研究了免疫检查点标记物的潜在协会。材料和方法：通过免疫组织化学分析VEGFR 1-3的表达水平，并与检查点标记物PD-1和PD-L1的表达相关。此外，研究了249名患有249名患者的肿瘤样本，与整体存活率和临床病理特征相关。 Kaplan-Meier分析和日志等级试验用于生存分析。通过χ2检验比较分类变量。结果：最常见的主要肿瘤部位是小肠（50.6％），其次是胰腺（25.7％）。 VEGFR 1在6.4％的59％，VEGFR 2中高表达，61.8％的VEGFR 3分析的样品。 VEGFR 1-3的表达与存活率没有显着相关。胰腺的NENs在80％的病例中具有最高的VEGFR 1和3的表达。 VEGFR 1-3阳性与免疫检查点标志物的表达水平相关。讨论：VEGFR 1-3显示了指示可想象的目标的神经内分泌瘤瘤的不同亚组中的不同表达模式。此外，VEGFRS和免疫检查点标志物之间存在大致关联。抗VEPFR治疗组合在一起，在GEP-NEN患者中代表着一种有前途的治疗方法，应该在未来的研究中解决。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号